Immunocore Holdings plc (IMCR) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Sell if holding. Multiple concerning factors at $28.93: Leverage penalty (D/E 1.1): -0.5; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.5).
Immunocore is a commercial-stage biotech with KIMMTRAK (tebentafusp) approved in 39 countries for HLA-A*02:01-positive metastatic uveal melanoma, generating $400M in 2025 net therapy revenue. US accounts for the majority of revenue ($257M); additional pipeline programs target... Read more
Sell if holding. Multiple concerning factors at $28.93: Leverage penalty (D/E 1.1): -0.5; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.5). Chart setup: Death cross but MACD improving, RSI 57. Score 6.0/10, moderate confidence.
Passes 8/10 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 79d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Recent Developments — Immunocore Holdings plc
Latest news
- H.C. Wainwright reiterates Immunocore stock rating citing KIMMTRAK penetration By Investing.com - Investing.com South Af — Investing.com South Africa positive
- IMCR Reiterated by HC Wainwright & Co. -- Price Target Maintained at $100 - GuruFocus — GuruFocus positive
- HC Wainwright Reiterates "Buy" Rating for Immunocore (NASDAQ:IMCR) - MarketBeat — MarketBeat positive
- Immunocore (IMCR): Clinical Momentum, Credible Management, and Industry Visibility Support Buy Rating - TipRanks — TipRanks positive
- Immunocore (IMCR) upgraded to strong buy: Here's why - MSN — MSN positive
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 ceiling hit
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Multiple concerning factors at $28.93: Leverage penalty (D/E 1.1): -0.5; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.5). Chart setup: Death cross but MACD improving, RSI 57. Prior stop was $26.90. Score 6.0/10, moderate confidence.
Take-profit target: $55.24 (+90.9% upside). Prior stop was $26.90. Stop-loss: $26.90.
V7 low-quality RISK_OFF penalty: -0.5 (Q=4.5); Leverage penalty (D/E 1.1): -0.5; Elevated risk factors.
Immunocore Holdings plc trades at a P/E of N/A (forward -42.1). TrendMatrix value score: 8.6/10. Verdict: Sell.
23 analysts cover IMCR with a consensus score of 4.1/5. Average price target: $63.
What does Immunocore Holdings plc do?Immunocore is a commercial-stage biotech with KIMMTRAK (tebentafusp) approved in 39 countries for HLA-A*02:01-positive...
Immunocore is a commercial-stage biotech with KIMMTRAK (tebentafusp) approved in 39 countries for HLA-A*02:01-positive metastatic uveal melanoma, generating $400M in 2025 net therapy revenue. US accounts for the majority of revenue ($257M); additional pipeline programs target cutaneous melanoma, ovarian cancer, NSCLC, HIV, and autoimmune disease using the ImmTAX bispecific platform. Manufacturing is fully outsourced to CMOs AGC Biologics and Simtra Biopharma.